- UAA Congress 2025

Back

Final Presentation Format

Eposter Presentation

Eposter in PDF Format

Accept format: PDF. The file size should not be more than 5MB

Eposter in Image Format

Accept format: PNG/JPG/WEBP. The file size should not be more than 2MB

Abstract

Abstract Title

Management of Small-Cell-Type Cancer of Prostate with Liver Metastases: A Retrospective Study of 3 Cases and Literature Review

Presentation Type

Non-Moderated Poster Abstract

Manuscript Type

Case Study

Abstract Category *

Oncology: Prostate

Author's Information

Number of Authors (including submitting/presenting author) *

No more than 10 authors can be listed (as per the Good Publication Practice (GPP) Guidelines).
Please ensure the authors are listed in the right order.

Co-author 1

Feng Gao 934563340@qq.com Hangzhou Hospital of Traditional Chinese Medicine Department of Urology hangzhou China *

Co-author 2

YingJun Jiang 1281694463@qq.com Hangzhou Hospital of Traditional Chinese Medicine Department of Urology hangzhou China

Co-author 3

Yasheng Huang kk2158@qq.com Hangzhou Hospital of Traditional Chinese Medicine Department of Urology hangzhou China

Co-author 4

Fei Tong 794815766@qq.com Zhujiang Hospital, Southern Medical University Department of Pharmacy Guangzhou China

Co-author 5

Ning Cao 2912626477@qq.com The Second Affiliated Hospital of Zhejiang Chinese Medical University Department of Pharmacy hangzhou China

Co-author 6

Dechen Ma 7562453@qq.com Hangzhou Hospital of Traditional Chinese Medicine Department of Urology hangzhou China

Co-author 7

Haote Chen 731320740@qq.com Hangzhou Hospital of Traditional Chinese Medicine Department of Urology hangzhou China

Co-author 8

Liping He 251957617@qq.com Hangzhou Hospital of Traditional Chinese Medicine Department of Urology hangzhou China

Co-author 9

Jingyu Zhu zjyurology@163.com Zhejiang Hospital of Integrated Traditional Chinese and Western Medicine Department of Urology hangzhou China

Co-author 10

Qiaoping Xu 945762752@qq.com Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou First People’s Hospital, Cancer Center, Westlake University Department of Clinical Pharmacology hangzhou China

Co-author 11

Co-author 12

Co-author 13

Co-author 14

Co-author 15

Co-author 16

Co-author 17

Co-author 18

Co-author 19

Co-author 20

Abstract Content

Introduction

Prostatic small-cell carcinoma (SmCC) is a rare, aggressive form of prostate cancer. That accounts for 0.5-2% of all cases of prostate cancer which associated with poor clinical outcomes. This study presents three cases of Small-Cell type Cancer of Prostate. The mean age at the time of diagnosis was 55 years. Our case series highlights the importance of considering a prostate primary, even in the setting of normal prostate-specific antigen (PSA) levels and aberrant immunohistochemistry profile, when diagnosing a metastatic neuroendocrine carcinoma in the liver. Careful correlation between the patient’s medical history, imaging and pathology findings is required. Furthermore, the results demonstrate that if small cell neuroendocrine carcinoma of the prostate (SCNECP) transfer to the liver, it indicates a particularly poor prognosis (OS: 7.8 months). The need for further study into therapeutic regimen for SCNECP is very important. The antiangiogenic drug, anlotinib may be useful for SCNECP. The efficacy and safety of anlotinib in the clinical treatment of SCNECP need further randomized clinical studies.

Materials and Methods

Results

Conclusions

Keywords

Small cell prostate cancer, Liver metastasis, Androgen deprivation therapy, Radiotherapy

Figure 1

Figure 1 Caption

Figure 2

Figure 2 Caption

Figure 3

Figure 3 Caption

Figure 4

Figure 4 Caption

Figure 5

Figure 5 Caption

Presentation Order